ArticleFrontiers in immunology2021
dmLT Adjuvant Enhances Cytokine Responses to T Cell Stimuli, Whole Cell Vaccine Antigens and Lipopolysaccharide in Both Adults and Infants.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 24 citations in OpenAlex.
- Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: a double-blind, randomised, placebo-controlled, phase 2b trial.The Lancet. Infectious diseases · 2026Trial
- The case for evaluation of double mutant heat-labile toxin as an adjuvant to improve oral cholera vaccine immunogenicity.Frontiers in immunology · 2026Trial
- Th1 and Th17 Responses to LTB and Colonization Factors Following Oral ETEC Vaccination.Microorganisms · 2026Article
- Systemic and mucosal immunity to enterotoxigenicFrontiers in immunology · 2026Review
- Article
- Conserved antigens for enteric vaccines.Vaccine · 2025Review
- Safety and immunogenicity in humans of enterotoxigenic Escherichia coli double mutant heat-labile toxin administered intradermally.NPJ vaccines · 2025Article
- Safety and immunogenicity of a recombinant double-mutant heat-labile toxin derived from enterotoxigenicFrontiers in bacteriology · 2025Article
- Dose-sparing effects of novel adjuvants and aluminum hydroxide on two different vaccines in a neonatal mouse model.Frontiers in immunology · 2025Article
- Pivotal role ofFrontiers in medicine · 2024Review
- A Perspective on the Strategy for Advancing ETVAXMicroorganisms · 2023Article
- Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen.NPJ vaccines · 2023Article
- Article
- Identifying a stable bulk dmLT adjuvant formulation at a clinically relevant concentration.Vaccine · 2023Article
- Broad protective vaccination against systemic Escherichia coli with autotransporter antigens.PLoS pathogens · 2023Article
- Oral inactivated whole cell vaccine for mucosal immunization: ETVAX case study.Frontiers in immunology · 2023Article
- Production of monoclonal antibody of heat-labile toxin A subunit to identify enterotoxigenicFrontiers in immunology · 2023Article
- T helper cell responses in adult diarrheal patients following natural infection with enterotoxigenicFrontiers in immunology · 2023Article
- Evaluation of Inhibitory Effect of Abatacept (CTLA4-ig) and Conditioned Medium of Mesenchymal Stem Cell in an Acetic Acid-induced Mouse Model of Acute Colitis.International journal of molecular and cellular medicine · 2023Article
- New-age vaccine adjuvants, their development, and future perspective.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enhancement of mucosal immune responses in children and infants using novel adjuvants such as double mutant heat labile toxin (dmLT) is an important goal in the enteric vaccine field. dmLT has been shown to enhance mucosal IgA responses to the oral inactivated enterotoxigenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.